Terms: = Kidney tumors AND PRCC, Q92733, TPRC, RCCP1, MGC4723, MGC17178, ENSG00000143294, 5546 AND Diagnosis
142 results:
1. Implications of MTHFD2 expression in renal cell carcinoma aggressiveness.
Silva RVN; Berzotti LA; Laia MG; Araújo LS; Silva CA; Ribeiro KB; Brandão M; Michelleti AMR; Machado JR; Lira RCP
PLoS One; 2024; 19(2):e0299353. PubMed ID: 38422037
[TBL] [Abstract] [Full Text] [Related]
2. Biphasic papillary (biphasic squamoid alveolar) renal cell carcinoma: a clinicopathologic and molecular study of 17 renal cell carcinomas including 10 papillary adenomas.
Nova-Camacho LM; Acosta AM; Akgul M; Panizo A; Galea LA; Val-Carreres A; Talavera JA; Guerrero-Setas D; Martin-Arruti M; Ruiz I; García-Martos M; Sangoi AR
Virchows Arch; 2024 Mar; 484(3):441-449. PubMed ID: 38388964
[TBL] [Abstract] [Full Text] [Related]
3. Clear-cell papillary renal cell tumour: New insights into clinicopathological features and molecular landscape after renaming by 5th WHO classification.
Zhang W; Zhang L; Wen Z; Liang J; Wang Y; Wang Z; Yin Z; Fan L
Pathol Res Pract; 2024 Mar; 255():155167. PubMed ID: 38324963
[TBL] [Abstract] [Full Text] [Related]
4. ALK-rearranged renal cell carcinoma (ALK-RCC): Evaluation of histomorphological and immunohistochemical features by analysis of 276 renal cell carcinoma cases in Turkey.
Doğan K; Onder E
Pathol Res Pract; 2024 Jan; 253():154951. PubMed ID: 38039739
[TBL] [Abstract] [Full Text] [Related]
5. Papillary Renal Cell Carcinoma: A Review of Prospective Clinical Trials.
Maughan BL; Sirohi D
Curr Treat Options Oncol; 2023 Sep; 24(9):1199-1212. PubMed ID: 37407886
[TBL] [Abstract] [Full Text] [Related]
6. Diagnostic performance of multiparametric magnetic resonance imaging in the differentiation of clear cell renal cell cancer.
Aydoğan C; Cansu A; Aydoğan Z; Erdemi S; Teymur A; Bektaş O; Mungan S; Kazaz İO
Abdom Radiol (NY); 2023 Jul; 48(7):2349-2360. PubMed ID: 37071122
[TBL] [Abstract] [Full Text] [Related]
7. Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination therapy.
Riveros C; Ranganathan S; Xu J; Chang C; Kaushik D; Morgan M; Miles BJ; Muhammad T; Anis M; Aghazadeh M; Zhang J; Efstathiou E; Klaassen Z; Brooks MA; Rini B; Wallis CJD; Satkunasivam R
Urol Oncol; 2023 Mar; 41(3):150.e1-150.e9. PubMed ID: 36610815
[TBL] [Abstract] [Full Text] [Related]
8. Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging: Diagnostic Pathways and Metabolites for Renal Tumor Entities.
Erlmeier F; Sun N; Shen J; Feuchtinger A; Buck A; Prade VM; Kunzke T; Schraml P; Moch H; Autenrieth M; Weichert W; Hartmann A; Walch A
Oncology; 2023; 101(2):126-133. PubMed ID: 36198279
[TBL] [Abstract] [Full Text] [Related]
9. The value of CT features and demographic data in the differential diagnosis of type 2 papillary renal cell carcinoma from fat-poor angiomyolipoma and oncocytoma.
Zhou C; Ban X; Luo L; Shi C
Abdom Radiol (NY); 2022 Nov; 47(11):3838-3846. PubMed ID: 36085376
[TBL] [Abstract] [Full Text] [Related]
10. TSC/MTOR -associated Eosinophilic Renal tumors Exhibit a Heterogeneous Clinicopathologic Spectrum : A Targeted Next-generation Sequencing and Gene Expression Profiling Study.
Xia QY; Wang XT; Zhao M; He HY; Fang R; Ye SB; Li R; Wang X; Zhang RS; Lu ZF; Ma HH; Wang ZY; Rao Q
Am J Surg Pathol; 2022 Nov; 46(11):1562-1576. PubMed ID: 35980750
[TBL] [Abstract] [Full Text] [Related]
11. Papillary renal neoplasm with reverse polarity-a comparative study with CCprcc, Oprcc, and prcc1.
Wang T; Ding X; Huang X; Ye J; Li H; Cao S; Gao Y; Ma X; Huang Q; Wang B
Hum Pathol; 2022 Nov; 129():60-70. PubMed ID: 35977593
[TBL] [Abstract] [Full Text] [Related]
12. [Clinicopathological features and prognostic analysis of papillary renal cell carcinoma].
Bo ES; Hong P; Zhang Y; Deng SH; Ge LY; Lu M; Li N; Ma LL; Zhang SD
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):615-620. PubMed ID: 35950382
[TBL] [Abstract] [Full Text] [Related]
13. GATA3 aids in distinguishing fumarate hydratase-deficient renal cell carcinoma from papillary renal cell carcinoma.
Liu Y; Dong Y; Gu Y; Xu H; Fan Y; Li X; Dong L; Zhou L; Yang X; Wang C
Ann Diagn Pathol; 2022 Oct; 60():152007. PubMed ID: 35841867
[TBL] [Abstract] [Full Text] [Related]
14. Papillary renal cell carcinoma: current and controversial issues.
Angori S; Lobo J; Moch H
Curr Opin Urol; 2022 Jul; 32(4):344-351. PubMed ID: 35674688
[TBL] [Abstract] [Full Text] [Related]
15. Clinical, pathological and long-term oncologic outcomes of papillary type I vs. type II renal cell carcinoma.
Basile G; Rosiello G; Larcher A; Fallara G; Martini A; Re C; Cignoli D; Tian Z; Karakiewicz PI; Mottrie A; Bertini R; Necchi A; Raggi D; Salonia A; Briganti A; Montorsi F; Capitanio U
Urol Oncol; 2022 Aug; 40(8):384.e15-384.e21. PubMed ID: 35662498
[TBL] [Abstract] [Full Text] [Related]
16. Long Non-Coding RNAs as Novel Biomarkers in the Clinical Management of Papillary Renal Cell Carcinoma Patients: A Promise or a Pledge?
Trevisani F; Floris M; Vago R; Minnei R; Cinque A
Cells; 2022 May; 11(10):. PubMed ID: 35626699
[TBL] [Abstract] [Full Text] [Related]
17. WHO 2022 landscape of papillary and chromophobe renal cell carcinoma.
Lobo J; Ohashi R; Amin MB; Berney DM; Compérat EM; Cree IA; Gill AJ; Hartmann A; Menon S; Netto GJ; Raspollini MR; Rubin MA; Tan PH; Tickoo SK; Tsuzuki T; Turajlic S; Zhou M; Srigley JR; Moch H
Histopathology; 2022 Oct; 81(4):426-438. PubMed ID: 35596618
[TBL] [Abstract] [Full Text] [Related]
18. Application of different methods used to measure the apparent diffusion coefficient of renal cell carcinoma on the same lesion and its correlation with ISUP nuclear grading.
Kılıçarslan G; Eroğlu Y; Kılıçarslan A
Abdom Radiol (NY); 2022 Jul; 47(7):2442-2452. PubMed ID: 35570223
[TBL] [Abstract] [Full Text] [Related]
19. Start of a New Era: Management of Non-Clear Cell Renal Cell Carcinoma in 2022.
Maughan BL
Curr Oncol Rep; 2022 Sep; 24(9):1201-1208. PubMed ID: 35438388
[TBL] [Abstract] [Full Text] [Related]
20. The prognostic impact of Claudin 6 in papillary renal cell carcinoma.
Mikuteit M; Zschäbitz S; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Steffens S; Erlmeier F
Pathol Res Pract; 2022 Mar; 231():153802. PubMed ID: 35180650
[TBL] [Abstract] [Full Text] [Related]
[Next]
